- Home
- SES vs LENZ Comparison
SES vs LENZ Comparison
Compare SES & LENZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SES | LENZ |
|---|---|---|
| Founded | 2012 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 719.2M | 609.5M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | SES | LENZ |
|---|---|---|
| Price | $1.73 | $13.57 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $4.00 | ★ $56.25 |
| AVG Volume (30 Days) | ★ 4.6M | 844.4K |
| Earning Date | 01-01-0001 | 04-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1,007.16 | N/A |
| Revenue Next Year | $131.04 | $157.21 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.38 | $11.48 |
| 52 Week High | $3.73 | $50.19 |
Technical Indicators
Market Signals| Indicator | SES | LENZ |
|---|---|---|
| Relative Strength Index (RSI) | 44.35 | 42.87 |
| Support Level | $1.62 | N/A |
| Resistance Level | $2.62 | $21.80 |
| Average True Range (ATR) | 0.12 | 0.88 |
| MACD | -0.01 | 0.16 |
| Stochastic Oscillator | 35.71 | 60.53 |
Price Performance
Historical ComparisonAbout SES SES AI Corporation
SES AI Corp is a developer and manufacturer of high-performance, AI-enhanced Lithium-Metal (Li-Metal) and Lithium-ion (Li-ion) rechargeable battery technologies for electric vehicles (EVs), Urban Air Mobility (UAM), drones, robotics, Battery Energy Storage Systems (BESS) and other applications. It includes Software and Hardware products that are EV, UAM, Drone, Molecular Universe, and Avatar.
About LENZ LENZ Therapeutics Inc.
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45.